WO2018226795A1 - Anticorps anti-n-cadhérine humanisés et leurs utilisations - Google Patents

Anticorps anti-n-cadhérine humanisés et leurs utilisations Download PDF

Info

Publication number
WO2018226795A1
WO2018226795A1 PCT/US2018/036211 US2018036211W WO2018226795A1 WO 2018226795 A1 WO2018226795 A1 WO 2018226795A1 US 2018036211 W US2018036211 W US 2018036211W WO 2018226795 A1 WO2018226795 A1 WO 2018226795A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
cadherin
sequence
amino acid
Prior art date
Application number
PCT/US2018/036211
Other languages
English (en)
Inventor
Kirstin A. ZETTLITZ
Anna M. Wu
Robert E. Reiter
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to EP18813498.5A priority Critical patent/EP3634476A4/fr
Priority to US16/619,496 priority patent/US20200165351A1/en
Publication of WO2018226795A1 publication Critical patent/WO2018226795A1/fr
Priority to US18/331,623 priority patent/US20240026025A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La présente invention concerne l'inhibition de la signalisation de la N-cadhérine à l'aide d'un anticorps anti-N-cadhérine humanisé. Selon un mode de réalisation, l'invention concerne des méthodes de traitement d'une maladie ou d'un trouble à médiation assurée par la N-cadhérine chez un individu par mise en contact de l'individu avec un anticorps anti-N-cadhérine humanisé.
PCT/US2018/036211 2017-06-06 2018-06-06 Anticorps anti-n-cadhérine humanisés et leurs utilisations WO2018226795A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP18813498.5A EP3634476A4 (fr) 2017-06-06 2018-06-06 Anticorps anti-n-cadhérine humanisés et leurs utilisations
US16/619,496 US20200165351A1 (en) 2017-06-06 2018-06-06 Humanized anti-n-cadherin antibodies and uses thereof
US18/331,623 US20240026025A1 (en) 2017-06-06 2023-06-08 Humanized anti-n-cadherin antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762515617P 2017-06-06 2017-06-06
US62/515,617 2017-06-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/619,496 A-371-Of-International US20200165351A1 (en) 2017-06-06 2018-06-06 Humanized anti-n-cadherin antibodies and uses thereof
US18/331,623 Continuation US20240026025A1 (en) 2017-06-06 2023-06-08 Humanized anti-n-cadherin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
WO2018226795A1 true WO2018226795A1 (fr) 2018-12-13

Family

ID=64565984

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/036211 WO2018226795A1 (fr) 2017-06-06 2018-06-06 Anticorps anti-n-cadhérine humanisés et leurs utilisations

Country Status (3)

Country Link
US (2) US20200165351A1 (fr)
EP (1) EP3634476A4 (fr)
WO (1) WO2018226795A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070231333A1 (en) * 2006-03-10 2007-10-04 Wyeth Anti-5t4 antibodies and uses thereof
US20100239571A1 (en) * 2006-08-25 2010-09-23 Seattle Genetics, Inc. CD30 Binding Agents and Uses Thereof
US20110086029A1 (en) * 2008-04-04 2011-04-14 The Regents Of The University Of California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
US20140017240A1 (en) * 2008-11-10 2014-01-16 The Regents Of The University Of California Fully Human Antibodies Against N-Cadherin
US20140371430A1 (en) * 2011-04-08 2014-12-18 H Lundbeck A/S Antibodies Specific to Pyroglutamated Abeta

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278821A1 (en) * 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
GB201119089D0 (en) * 2011-11-04 2011-12-21 Isis Innovation Treatment of musculoskeletal fibroproliferative disorders
EP2830659A1 (fr) * 2012-03-27 2015-02-04 Novartis AG Traitement de la fibrose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070231333A1 (en) * 2006-03-10 2007-10-04 Wyeth Anti-5t4 antibodies and uses thereof
US20100239571A1 (en) * 2006-08-25 2010-09-23 Seattle Genetics, Inc. CD30 Binding Agents and Uses Thereof
US20110086029A1 (en) * 2008-04-04 2011-04-14 The Regents Of The University Of California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
US20140017240A1 (en) * 2008-11-10 2014-01-16 The Regents Of The University Of California Fully Human Antibodies Against N-Cadherin
US20140371430A1 (en) * 2011-04-08 2014-12-18 H Lundbeck A/S Antibodies Specific to Pyroglutamated Abeta

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3634476A4 *

Also Published As

Publication number Publication date
US20200165351A1 (en) 2020-05-28
US20240026025A1 (en) 2024-01-25
EP3634476A1 (fr) 2020-04-15
EP3634476A4 (fr) 2021-06-02

Similar Documents

Publication Publication Date Title
CN108350084B (zh) 新的间皮素抗体和包含其的组合物
US10654920B2 (en) Anti-laminin4 antibodies specific for LG4-5
US20220235143A1 (en) Humanized antibodies to mucin-16 and methods of use thereof
US20230331867A1 (en) Nectin-4 antibodies and uses thereof
WO2021213466A1 (fr) Anticorps anti-cd73 et son utilisation
JP2010524433A (ja) ヒト腫瘍細胞に結合するヒト抗ｃｄ１６６抗体
JP6947435B2 (ja) 炭酸脱水素酵素に結合する抗体およびその用途
CN112334484A (zh) 抗-CD3ε抗体及其应用方法
KR102486507B1 (ko) 플렉틴-1 결합 항체 및 그의 용도
WO2014102299A2 (fr) Anticorps anti-lamp1 et conjugués anticorps médicament, et utilisations associées
US10975160B2 (en) Antibody binding to carbonic anhydrase and use thereof
KR20220009910A (ko) Ptk7에 특이적으로 결합하는 항체 및 이의 용도
US20240026025A1 (en) Humanized anti-n-cadherin antibodies and uses thereof
CN114853890A (zh) 一种prlr抗原结合蛋白及其制备方法和应用
CA3089300A1 (fr) Anticorps, fragment fonctionnel ou sonde de celui-ci contre des antigenes tumoraux
JP2015196665A (ja) 中和活性を有する抗ｌｒ１１モノクローナル抗体、及びそれを含有してなる医薬
WO2022166987A1 (fr) Anticorps se liant à lag-3 et leur utilisation
WO2022089644A1 (fr) Anticorps entièrement humain ciblant cd5, récepteur antigénique chimérique entièrement humain (car) et utilisation associée
US20210395371A1 (en) Preparation and use of anti-met-and-ron bispecific antibody and antibody-drug conjugate thereof
JP2024508304A (ja) Ｃｌａｕｄｉｎ－６に対する抗体およびそれの使用
CN112153983A (zh) 抗ngly-1抗体及使用方法
CN117597362A (zh) 抗紧密连接蛋白-6的抗体及其用途
Sun Development of Antibody Modulators for an Oncogenic Potassium Channel
NZ616809B2 (en) Anti-b7-h3 antibody

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18813498

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018813498

Country of ref document: EP

Effective date: 20200107